EU
EIDX

Emory University’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Emory University’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-67,753
Closed -$2.44M – 16
2019
Q3 		$2.44M Sell
67,753
-16,083
-19% -$628K 4.81% 2
2019
Q2 		$2.61M Buy
+83,836
New +$2.27M 1.83% 8

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Emory University's EIDX Position: Q4 2019 in Review

Emory University sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2019, closing a stake of 67,753 shares — an estimated $2.44M sold.

Emory University first reported a position in EIDX in Q2 2019 and held it in 2 quarters. The position peaked at $2.61M in Q2 2019. 102 funds tracked by Wall St. Rank hold EIDX as of Q4 2019.

  • Emory University reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Emory University sold 67,753 Eidos Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $2.44M.
  • Emory University first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Emory University's Eidos Therapeutics, Inc. Common Stock position peaked at $2.61M in Q2 2019.
  • 102 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Emory University's 13F filing for Q4 2019, filed 13 Feb 2020.